Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04089449 | A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas | PHASE1 | COMPLETED | 86 | — | — | Nov 6, 2019 | Mar 28, 2023 | Apr 5, 2023 | 11 | United States |
Dose limiting toxicities will be evaluated through the first cycle
The MTD will be established for further investigation in participants with solid tumors and gliomas
The RP2D will be established for further investigation in participants with solid tumors and gliomas
| Arm | Type | Description |
|---|---|---|
| PRT811 | EXPERIMENTAL | PRT811 will be administered orally |
| Name | Type | Description |
|---|---|---|
| PRT811 | DRUG | PRT811 will be administered orally |
Inclusion Criteria: * Malignancies that are refractory to or intolerant of established therapies known to provide clinical benefit for the malignancy in question, or in the opinion of the Investigator, not be a candidate for such therapies * Subjects must have recovered from the effects of any prio...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |